Want to join the conversation?
Millendo Therapeutics said it has entered into an exclusive license agreement with $AZN for worldwide development and commercialization rights to AZD4901, product candidate for treatment of polycystic ovary syndrome (PCOS), the most common endocrine disease in women. Millendo will develop the compound as MLE4901.
$TSLA opening a showroom in Michigan. A bold move !!
$SGY is expected to achieve $6.17 price target in next year, with a minimum target of $3.00, due to the price increase of 27.85% to $6.29 during the last trading session.
$SWHC showing consistent increase in sales for the past three quarters suggesting the US craze for firearms is not going to subside soon.